JP2022512900A5 - - Google Patents
Info
- Publication number
- JP2022512900A5 JP2022512900A5 JP2021523897A JP2021523897A JP2022512900A5 JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5 JP 2021523897 A JP2021523897 A JP 2021523897A JP 2021523897 A JP2021523897 A JP 2021523897A JP 2022512900 A5 JP2022512900 A5 JP 2022512900A5
- Authority
- JP
- Japan
- Prior art keywords
- represented
- formula
- bifunctional compound
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754934P | 2018-11-02 | 2018-11-02 | |
| US62/754,934 | 2018-11-02 | ||
| PCT/US2019/059401 WO2020092907A1 (en) | 2018-11-02 | 2019-11-01 | Acetylation writer inhibitor development and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512900A JP2022512900A (ja) | 2022-02-07 |
| JP2022512900A5 true JP2022512900A5 (enExample) | 2022-11-08 |
| JP7712867B2 JP7712867B2 (ja) | 2025-07-24 |
Family
ID=70463920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523897A Active JP7712867B2 (ja) | 2018-11-02 | 2019-11-01 | アセチル化ライター阻害剤の開発およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12428412B2 (enExample) |
| EP (1) | EP3873898B1 (enExample) |
| JP (1) | JP7712867B2 (enExample) |
| CN (1) | CN112969696B (enExample) |
| AU (1) | AU2019371400B2 (enExample) |
| CA (1) | CA3118597A1 (enExample) |
| ES (1) | ES3038078T3 (enExample) |
| WO (1) | WO2020092907A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN111217802B (zh) * | 2018-11-27 | 2021-10-08 | 海创药业股份有限公司 | 一类组蛋白乙酰化酶p300抑制剂及其用途 |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| WO2020257278A2 (en) * | 2019-06-18 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Small molecule target bromo/acetyl proteins and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| CN116133692A (zh) | 2020-07-30 | 2023-05-16 | 凯麦拉医疗公司 | 治疗突变淋巴瘤的方法 |
| WO2022042707A1 (en) * | 2020-08-27 | 2022-03-03 | Cullgen (Shanghai) , Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| US20240122941A1 (en) * | 2020-12-25 | 2024-04-18 | National Cancer Center | Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| AU2022233431B2 (en) * | 2021-03-09 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | Ep300 degrader and uses thereof in neuroblastoma |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| CN116375717B (zh) * | 2021-12-30 | 2025-10-28 | 成都先导药物开发股份有限公司 | 螺环化合物及其双功能化合物和用途 |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| GB202209404D0 (en) * | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
| JP2025137900A (ja) * | 2022-08-10 | 2025-09-25 | 住友ファーマ株式会社 | 第４級炭素で置換された３級アミド誘導体 |
| JP2025524008A (ja) * | 2022-09-07 | 2025-07-25 | 成都先導薬物開発股▲フン▼有限公司 | スピロ化合物及びその用途 |
| CN119255996B (zh) * | 2022-09-08 | 2026-04-24 | 成都先导药物开发股份有限公司 | 螺环化合物及其用途 |
| WO2024064358A1 (en) * | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR20250075705A (ko) | 2022-10-07 | 2025-05-28 | 화이자 인코포레이티드 | Hsd17b13 억제제 및/또는 분해제 |
| EP4634169A1 (en) | 2022-12-16 | 2025-10-22 | Pfizer Inc. | 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof |
| CN116178339B (zh) * | 2023-02-20 | 2024-08-06 | 杭州医学院 | 以含氧烷烃为连接链的hdac降解剂及其制备方法和应用 |
| GB202302941D0 (en) | 2023-02-28 | 2023-04-12 | Tocris Cookson Ltd | Proteolysis-targeting chimeras |
| WO2025120592A1 (en) | 2023-12-07 | 2025-06-12 | Pfizer Inc. | Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2013039854A1 (en) | 2011-09-15 | 2013-03-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| US20160235716A1 (en) * | 2014-09-18 | 2016-08-18 | Abbvie Inc. | Spirocyclic hat inhibitors and methods for their use |
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) * | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| KR20190084063A (ko) * | 2016-10-28 | 2019-07-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Ｅｚｈ２-매개성 암 치료용 조성물 및 방법 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2020257278A2 (en) * | 2019-06-18 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Small molecule target bromo/acetyl proteins and uses thereof |
-
2019
- 2019-11-01 CN CN201980072584.4A patent/CN112969696B/zh active Active
- 2019-11-01 AU AU2019371400A patent/AU2019371400B2/en active Active
- 2019-11-01 EP EP19878099.1A patent/EP3873898B1/en active Active
- 2019-11-01 WO PCT/US2019/059401 patent/WO2020092907A1/en not_active Ceased
- 2019-11-01 CA CA3118597A patent/CA3118597A1/en active Pending
- 2019-11-01 ES ES19878099T patent/ES3038078T3/es active Active
- 2019-11-01 JP JP2021523897A patent/JP7712867B2/ja active Active
- 2019-11-01 US US17/289,662 patent/US12428412B2/en active Active
-
2025
- 2025-07-08 US US19/262,282 patent/US20250333402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512900A5 (enExample) | ||
| KR100346795B1 (ko) | 헤테로원자-포함 리간드 및 이의 금속 착화합물 | |
| JP2023551355A (ja) | 抗腫瘍化合物並びにその調製方法及び使用 | |
| JP2022166014A5 (enExample) | ||
| IL312845B1 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| JP2019534034A5 (enExample) | ||
| JP2006511534A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2018511628A5 (enExample) | ||
| CA2479109A1 (en) | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands | |
| JP2010535713A5 (enExample) | ||
| JP3187535B2 (ja) | 医薬的に活性なヒドラジン誘導体およびその製造方法 | |
| JP2022543231A5 (enExample) | ||
| JP2006507265A5 (enExample) | ||
| JP2021510376A5 (enExample) | ||
| JP2014500870A5 (enExample) | ||
| JP2022549510A5 (enExample) | ||
| JPS635033A (ja) | 化合物標的化組成物 | |
| JP2018516243A5 (enExample) | ||
| JP2021503915A5 (enExample) | ||
| JP2021525730A5 (enExample) | ||
| JP2021530444A5 (enExample) | ||
| JP2024504471A5 (enExample) | ||
| JP2022510505A5 (enExample) | ||
| JP2012520321A5 (enExample) |